Cellectis SA ( (CLLS) ) just unveiled an update.
On April 28, 2025, Cellectis announced advancements in non-viral gene editing and base editing at the ASGCT Annual Meeting. The company presented research on TALEN®-mediated non-viral transgene insertion and TALE base editors, highlighting their potential to improve cellular and gene therapies. These innovations aim to address challenges associated with traditional methods, offering safer and more efficient therapeutic options for diseases such as cancer and autoimmune disorders.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s stock score is influenced by its strong strategic collaborations, notably with AstraZeneca, which enhance its financial stability and extend its cash runway. However, the company’s ongoing challenges with profitability and mixed technical signals weigh down the overall score. The positive earnings call sentiment and future clinical trial advancements are significant positives, whereas current valuation metrics and profitability issues are key concerns.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that utilizes a pioneering gene-editing platform to develop cell and gene therapies. The company focuses on allogeneic CAR T immunotherapies for oncology and gene therapies for other therapeutic indications. Cellectis is notable for its end-to-end control of the cell and gene therapy value chain, with headquarters in Paris and additional locations in New York and Raleigh.
YTD Price Performance: -15.47%
Average Trading Volume: 346,461
Technical Sentiment Signal: Strong Buy
Current Market Cap: $112.9M
For a thorough assessment of CLLS stock, go to TipRanks’ Stock Analysis page.